Neurology News

Supernus Pharmaceuticals Inc. announced that the FDA has issued a complete response letter for its new drug application of SPN-830, requesting more information.

Antidepressant use in pregnancy was not associated with neurodevelopmental disorders in offspring, according to a cohort study published in JAMA Internal Medicine.

SAN DIEGO – Athira Pharma’s first intervention trial involving fosgonimeton showed that use of the drug alone showed a “sizable effect” in cognitive improvement at 26 weeks, according to chief medical officer Hans Moebius, MD, PhD.

The National Football League and the NFL Players Association have issued a joint statement finalizing review of the league’s concussion protocol, which now prohibits a player from returning to a game if diagnosed with ataxia.

Biotechnology company Oligomerix announced a $2.49 million award from the NIH to support phase 1b studies of OLX-07010, an oral tau self-association small molecule inhibitor, according to a company press release.

ANAHEIM, Calif. — Findings presented here suggest that young athletes may be at greater risk for head injuries on synthetic turf vs. natural grass fields.

The city of Philadelphia has issued a formal apology for the experiments conducted by the University of Pennsylvania at Philadelphia’s Holmesburg Prison from the 1950s to 1970s, according to a press release.

LAS VEGAS — Cannabinoids have been shown to effectively control seizures across the epilepsy spectrum; however, quality control of products remains a challenge, according to a presenter at BRAINWeek 2022.

SAN DIEGO – AmyriAD Therapeutics is focusing on the upregulation of neurotransmission to improve cognition and global function in patients with Alzheimer’s disease, according to CEO Sharon L. Rogers, PhD.

Neurological disorders like epilepsy can have significant, life-altering implications for patients, their families and caregivers.